Avitinib

Drug Profile

Avitinib

Alternative Names: AC0010; Avitinib maleate

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Hangzhou ACEA Pharmaceutical Research
  • Developer Hangzhou ACEA Pharmaceutical Research; Sun Yat-Sen University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 07 Apr 2017 Phase-I/II development for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) is ongoing in China (PO)
  • 22 Feb 2017 Hangzhou ACEA Pharmaceutical plans a phase III trial for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (NCT03058094)
  • 07 Oct 2016 Efficacy and safety data from a phase I/II trial in Non-small cell lung cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top